Healthcare and Life Sciences Deals Attorneys Expect in 2025

Mike Riella’s commentary was included in a Law360 article addressing major themes and trends healthcare and life sciences lawyers are expecting to see in 2025.

Mike tells Law360 about deal activity he expects to see in the year ahead, stating that both Big Pharma and smaller biotechs would be looking to make deals in 2025. "That's where M&A comes in," he said. "You have larger pharma companies, larger biotechs, with the wherewithal to actually move those products into device candidates forward." While it's hard to pinpoint exactly how much more dealmaking is expected in 2025 compared to 2024, Mike said it was clear that later-stage companies with mature programs and good data were most likely to become acquisition targets. "One of the nice things about this industry is in many ways it's very objective. Your data shows you have a promising product, or it doesn't," Mike observed.

Mike said that despite challenges associated with artificial intelligence, he expects to see more deals — a mixture of joint ventures, acquisitions and collaborations — where AI is a key component.